1. Home
  2. RIGL vs ETO Comparison

RIGL vs ETO Comparison

Compare RIGL & ETO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • ETO
  • Stock Information
  • Founded
  • RIGL 1996
  • ETO 2004
  • Country
  • RIGL United States
  • ETO United States
  • Employees
  • RIGL N/A
  • ETO N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • ETO Investment Managers
  • Sector
  • RIGL Health Care
  • ETO Finance
  • Exchange
  • RIGL Nasdaq
  • ETO Nasdaq
  • Market Cap
  • RIGL 486.4M
  • ETO 419.2M
  • IPO Year
  • RIGL 2000
  • ETO N/A
  • Fundamental
  • Price
  • RIGL $21.81
  • ETO $26.06
  • Analyst Decision
  • RIGL Buy
  • ETO
  • Analyst Count
  • RIGL 5
  • ETO 0
  • Target Price
  • RIGL $34.80
  • ETO N/A
  • AVG Volume (30 Days)
  • RIGL 347.9K
  • ETO 26.5K
  • Earning Date
  • RIGL 03-04-2025
  • ETO 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • ETO 6.67%
  • EPS Growth
  • RIGL N/A
  • ETO N/A
  • EPS
  • RIGL 0.22
  • ETO N/A
  • Revenue
  • RIGL $157,374,000.00
  • ETO N/A
  • Revenue This Year
  • RIGL $51.34
  • ETO N/A
  • Revenue Next Year
  • RIGL $15.75
  • ETO N/A
  • P/E Ratio
  • RIGL $98.50
  • ETO N/A
  • Revenue Growth
  • RIGL 21.65
  • ETO N/A
  • 52 Week Low
  • RIGL $7.48
  • ETO $19.85
  • 52 Week High
  • RIGL $29.82
  • ETO $25.21
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 64.53
  • ETO 60.01
  • Support Level
  • RIGL $17.28
  • ETO $25.07
  • Resistance Level
  • RIGL $18.25
  • ETO $25.80
  • Average True Range (ATR)
  • RIGL 1.37
  • ETO 0.38
  • MACD
  • RIGL 0.65
  • ETO 0.09
  • Stochastic Oscillator
  • RIGL 99.68
  • ETO 99.61

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About ETO Eaton Vance Tax-Advantage Global Dividend Opp

Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas and consumable fuels, personal products, and other areas.

Share on Social Networks: